← Back to patent-cliff list
Tuvusertib
Tier C — Watch / tradeTuvusertib
Emd Serono Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ATR
Indications (approved)：星形细胞瘤, Endometrial cancer, Ovarian cancer, Merkel细胞癌, Breast cancer, Prostate cancer, Castration-resistant prostate cancer, Colorectal cancer
Regional status
US
Phase II
2023-09-13
EU
Phase II
2023-09-13
China
Phase I
2019-12-20
Japan
Phase II
2023-09-13
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tuvusertib?
Approved indications include: 星形细胞瘤, Endometrial cancer, Ovarian cancer, Merkel细胞癌, Breast cancer, Prostate cancer, Castration-resistant prostate cancer, Colorectal cancer.
When does the Tuvusertib patent expire?
No public expiry year is available for Tuvusertib yet; this page updates once verified.
How do I get a quote for Tuvusertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22